Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.

Wolkenberg SE, Nolt MB, Bilodeau MT, Trotter BW, Manley PJ, Kett NR, Nanda KK, Wu Z, Cato MJ, Kane SA, Kiss L, Spencer RH, Wang J, Lynch JJ, Regan CP, Stump GL, Li B, White R, Yeh S, Dinsmore CJ, Lindsley CW, Hartman GD.

Bioorg Med Chem Lett. 2017 Feb 15;27(4):1062-1069. doi: 10.1016/j.bmcl.2016.12.054. Epub 2017 Jan 16.

PMID:
28131713
2.

Characterization of an investigative safety pharmacology model to assess comprehensive cardiac function and structure in chronically instrumented conscious beagle dogs.

Regan CP, Stump GL, Detwiler TJ, Chen L, Regan HK, Gilberto DB, DeGeorge JJ, Sannajust FJ.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:107-14. doi: 10.1016/j.vascn.2016.05.002. Epub 2016 May 7.

PMID:
27166580
3.

The prototype serotonin 5-HT 1B/1D agonist sumatriptan increases the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis.

Lynch JJ Jr, Stump GL, Kane SA, Regan CP.

J Cardiovasc Pharmacol. 2009 Jun;53(6):474-9. doi: 10.1097/FJC.0b013e3181a71a61.

PMID:
19430309
4.

Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis.

Regan CP, Stump GL, Kane SA, Lynch JJ Jr.

J Pharmacol Exp Ther. 2009 Feb;328(2):571-8. doi: 10.1124/jpet.108.144220. Epub 2008 Nov 7.

PMID:
18997059
5.
6.

Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.

Nguyen KT, Claiborne CF, McCauley JA, Libby BE, Claremon DA, Bednar RA, Mosser SD, Gaul SL, Connolly TM, Condra CL, Bednar B, Stump GL, Lynch JJ, Koblan KS, Liverton NJ.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):3997-4000. Epub 2007 Apr 29.

PMID:
17498948
7.

In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate.

Regan CP, Stump GL, Wallace AA, Anderson KD, McIntyre CJ, Liverton NJ, Lynch JJ Jr.

J Cardiovasc Pharmacol. 2007 Apr;49(4):236-45.

PMID:
17438409
8.

Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.

Liverton NJ, Bednar RA, Bednar B, Butcher JW, Claiborne CF, Claremon DA, Cunningham M, DiLella AG, Gaul SL, Libby BE, Lyle EA, Lynch JJ, McCauley JA, Mosser SD, Nguyen KT, Stump GL, Sun H, Wang H, Yergey J, Koblan KS.

J Med Chem. 2007 Feb 22;50(4):807-19. Epub 2007 Jan 24.

PMID:
17249648
9.

Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.

Trotter BW, Nanda KK, Kett NR, Regan CP, Lynch JJ, Stump GL, Kiss L, Wang J, Spencer RH, Kane SA, White RB, Zhang R, Anderson KD, Liverton NJ, McIntyre CJ, Beshore DC, Hartman GD, Dinsmore CJ.

J Med Chem. 2006 Nov 30;49(24):6954-7.

PMID:
17125248
10.

Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.

Nanda KK, Nolt MB, Cato MJ, Kane SA, Kiss L, Spencer RH, Wang J, Lynch JJ, Regan CP, Stump GL, Li B, White R, Yeh S, Bogusky MJ, Bilodeau MT, Dinsmore CJ, Lindsley CW, Hartman GD, Wolkenberg SE, Trotter BW.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5897-901. Epub 2006 Sep 1.

PMID:
16949818
11.

Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats.

Brochu RM, Dick IE, Tarpley JW, McGowan E, Gunner D, Herrington J, Shao PP, Ok D, Li C, Parsons WH, Stump GL, Regan CP, Lynch JJ Jr, Lyons KA, McManus OB, Clark S, Ali Z, Kaczorowski GJ, Martin WJ, Priest BT.

Mol Pharmacol. 2006 Mar;69(3):823-32. Epub 2005 Nov 21.

PMID:
16301337
12.

In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide.

Stump GL, Wallace AA, Regan CP, Lynch JJ Jr.

J Pharmacol Exp Ther. 2005 Dec;315(3):1362-7. Epub 2005 Sep 12.

PMID:
16157659
13.

NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.

McCauley JA, Theberge CR, Romano JJ, Billings SB, Anderson KD, Claremon DA, Freidinger RM, Bednar RA, Mosser SD, Gaul SL, Connolly TM, Condra CL, Xia M, Cunningham ME, Bednar B, Stump GL, Lynch JJ, Macaulay A, Wafford KA, Koblan KS, Liverton NJ.

J Med Chem. 2004 Apr 8;47(8):2089-96.

PMID:
15056006
14.

In vivo canine cardiac electrophysiologic profile of 1,4-benzodiazepine IKs blockers.

Stump GL, Smith GR, Tebben AJ, Jahansouz H, Salata JJ, Selnick HG, Claremon DA, Lynch JJ Jr.

J Cardiovasc Pharmacol. 2003 Jul;42(1):105-12.

PMID:
12827034
15.

Benzodiazepines as potent and selective bradykinin B1 antagonists.

Wood MR, Kim JJ, Han W, Dorsey BD, Homnick CF, DiPardo RM, Kuduk SD, MacNeil T, Murphy KL, Lis EV, Ransom RW, Stump GL, Lynch JJ, O'Malley SS, Miller PJ, Chen TB, Harrell CM, Chang RS, Sandhu P, Ellis JD, Bondiskey PJ, Pettibone DJ, Freidinger RM, Bock MG.

J Med Chem. 2003 May 8;46(10):1803-6.

PMID:
12723943
16.

Orally efficacious NR2B-selective NMDA receptor antagonists.

Claiborne CF, McCauley JA, Libby BE, Curtis NR, Diggle HJ, Kulagowski JJ, Michelson SR, Anderson KD, Claremon DA, Freidinger RM, Bednar RA, Mosser SD, Gaul SL, Connolly TM, Condra CL, Bednar B, Stump GL, Lynch JJ, Macaulay A, Wafford KA, Koblan KS, Liverton NJ.

Bioorg Med Chem Lett. 2003 Feb 24;13(4):697-700.

PMID:
12639561
17.

Antiarrhythmic efficacy of combined I(Ks) and beta-adrenergic receptor blockade.

Lynch JJ Jr, Salata JJ, Wallace AA, Stump GL, Gilberto DB, Jahansouz H, Liverton NJ, Selnick HG, Claremon DA.

J Pharmacol Exp Ther. 2002 Jul;302(1):283-9.

PMID:
12065728
18.

Non-peptide alpha(v)beta(3) antagonists. Part 3: identification of potent RGD mimetics incorporating novel beta-amino acids as aspartic acid replacements.

Coleman PJ, Brashear KM, Hunt CA, Hoffman WF, Hutchinson JH, Breslin MJ, McVean CA, Askew BC, Hartman GD, Rodan SB, Rodan GA, Leu CT, Prueksaritanont T, Fernandez-Metzler C, Ma B, Libby LA, Merkle KM, Stump GL, Wallace AA, Lynch JJ, Lynch R, Duggan ME.

Bioorg Med Chem Lett. 2002 Jan 7;12(1):31-4.

PMID:
11738567
19.

Arrhythmogenic potential of positive inotropic agents.

Stump GL, Wallace AA, Gilberto DB, Gehret JR, Lynch JJ Jr.

Basic Res Cardiol. 2000 Jun;95(3):186-98.

PMID:
10879620
20.

Antiarrhythmic efficacy of selective blockade of the cardiac slowly activating delayed rectifier current, I(Ks), in canine models of malignant ischemic ventricular arrhythmia.

Lynch JJ Jr, Houle MS, Stump GL, Wallace AA, Gilberto DB, Jahansouz H, Smith GR, Tebben AJ, Liverton NJ, Selnick HG, Claremon DA, Billman GE.

Circulation. 1999 Nov 2;100(18):1917-22.

PMID:
10545437
22.

Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.

Cook JJ, Gardell SJ, Holahan MA, Sitko GR, Stump GL, Wallace AA, Gilberto DB, Hare TR, Krueger JA, Dyer DL, Sanderson PE, Vacca JP, Shafer JA, Lynch JJ Jr.

J Pharmacol Exp Ther. 1999 Apr;289(1):503-10.

PMID:
10087043
23.

Nonpeptide glycoprotein IIb/IIIa inhibitors: 14: oral antithrombotic efficacy of L-738,167 in a conscious canine model of coronary artery electrolytic injury.

Cook JJ, Glass JD, Sitko GR, Holahan MA, Stupienski RF 3rd, Wallace AA, Stump GL, Hand EL, Askew BC, Hartman GD, Gould RJ, Lynch JJ Jr.

Circulation. 1997 Aug 5;96(3):949-58.

PMID:
9264506
24.

Differential efficacy of the class III agent MK-499 against programmed stimulation-induced and ischemic-induced ventricular arrhythmias in a canine model of previous myocardial infarction.

Lynch JJ Jr, Wallace AA, Stump GL, Stupienski RF 3rd, Kothstein T, Gehret JR.

J Pharmacol Exp Ther. 1996 May;277(2):671-8.

PMID:
8627544
25.

Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.

Damiano BP, Giardino EC, Haertlein BJ, Stump GL, Mitchell JA, Falotico R.

J Cardiovasc Pharmacol. 1994 Feb;23(2):300-10.

PMID:
7511761
26.

In vivo cardiac electrophysiologic effects of RWJ 29009, a new potassium-channel activator, in comparison to cromakalim and nicardipine.

Damiano BP, Stump GL, Cheung WM, Salata JJ.

J Cardiovasc Pharmacol. 1993 Jul;22(1):143-52.

PMID:
7690086
27.

Investigation of electrophysiologic mechanisms for the antiarrhythmic actions of R 56865 in cardiac glycoside toxicity.

Damiano BP, Stump GL, Yagel SK.

J Cardiovasc Pharmacol. 1991 Sep;18(3):415-28.

PMID:
1720842
28.

Cardiac electrophysiologic effects of McN-5691, a new calcium-channel blocking antihypertensive agent.

Damiano BP, Flaim SF, Gill A, Stump GL, Brannan MD.

J Cardiovasc Pharmacol. 1990 Oct;16(4):546-56.

PMID:
1706795

Supplemental Content

Loading ...
Support Center